Preclinical Evidence That Trametinib Enhances the Response to Tyrosine Kinase Inhibitors in Acute Myeloid Leukemia

被引：1

作者：

Martinez-Lopez, Joaquin ^{[1
]}

Linares, Maria ^{[2
]}

Morales, Maria Luz ^{[2
]}

Arenas, Alicia ^{[1
]}

Zagorac, Ivana ^{[3
]}

Ayala, Rosa M. ^{[1
]}

Castro, Nerea ^{[4
]}

Rapado, Inmaculada ^{[5
]}

Quintela-Fandino, Miguel ^{[3
]}

机构：

[1] Octubre Hosp, Dept Hematol, Madrid, Spain

[2] Hosp 12 Octubre, Inst Invest, Madrid, Spain

[3] Ctr Nacl Invest Oncol, Madrid, Spain

[4] Hosp Octubre, Ser Hematol, Madrid, Spain

[5] Hosp Univ 12 Octubre, Madrid, Spain

来源：

BLOOD | 2016年 / 128卷 / 22期

关键词：

D O I：

10.1182/blood.V128.22.1581.1581

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

1581

引用

页数：4

共 50 条

[21] New tyrosine kinase inhibitors in chronic myeloid leukemia
Kantarjian, Hagop
Cortes, Jorge
CANCER INVESTIGATION, 2007, 25 : 41 - 43
[22] Inhibition of Xanthine Oxidoreductase Enhances the Potential of Tyrosine Kinase Inhibitors against Chronic Myeloid Leukemia
Romo-Gonzalez, Marta
Moreno-Paz, Sara
Garcia-Hernandez, Violeta
Sanchez-Guijo, Fermin
Hernandez-Hernandez, Angel
ANTIOXIDANTS, 2020, 9 (01)
[23] Preclinical efficacy for a novel tyrosine kinase inhibitor, ArQule 531 against acute myeloid leukemia
Elgamal, Ola A.
Mehmood, Abeera
Jeon, Jae Yoon
Carmichael, Bridget
Lehman, Amy
Orwick, Shelley J.
Truxall, Jean
Goettl, Virginia M.
Wasmuth, Ronni
Tran, Minh
Mitchell, Shaneice
Lapalombella, Rosa
Eathiraj, Sudharshan
Schwartz, Brian
Stegmaier, Kimberly
Baker, Sharyn D.
Hertlein, Erin
Byrd, John C.
JOURNAL OF HEMATOLOGY & ONCOLOGY, 2020, 13 (01)
[24] Preclinical efficacy for a novel tyrosine kinase inhibitor, ArQule 531 against acute myeloid leukemia
Ola A. Elgamal
Abeera Mehmood
Jae Yoon Jeon
Bridget Carmichael
Amy Lehman
Shelley J. Orwick
Jean Truxall
Virginia M. Goettl
Ronni Wasmuth
Minh Tran
Shaneice Mitchell
Rosa Lapalombella
Sudharshan Eathiraj
Brian Schwartz
Kimberly Stegmaier
Sharyn D. Baker
Erin Hertlein
John C. Byrd
Journal of Hematology & Oncology, 13
[25] Significant preclinical antileukemic activity of the tyrosine kinase inhibitor BVT I in acute myeloid leukemia
Eriksson, S.
Hassan, S.
Hoglund, M.
Larsson, R.
Lindhagen, E.
Aleskog, A.
Lothgren, A.
Fohlenhag, K.
Jensen, A. Jenmalm
Parrow, V.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2007, 92 : 114 - 115
[26] Multitargeted tyrosine kinase inhibitors in regulation of growth and survival of acute myeloid leukemia cells
Lasota, M.
Balwierz, W.
FEBS JOURNAL, 2014, 281 : 488 - 488
[27] Gold nanoparticles enhance the effect of tyrosine kinase inhibitors in acute myeloid leukemia therapy
Petrushev, Bobe
Boca, Sanda
Simon, Timea
Berce, Cristian
Frinc, Ioana
Dima, Delia
Selicean, Sonia
Gafencu, Grigore-Aristide
Tanase, Alina
Zdrenghea, Mihnea
Florea, Adrian
Suarasan, Sorina
Dima, Liana
Stanciu, Raluca
Jurj, Ancuta
Buzoianu, Anca
Cucuianu, Andrei
Astilean, Simion
Irimie, Alexandru
Tomuleasa, Ciprian
Berindan-Neagoe, Ioana
INTERNATIONAL JOURNAL OF NANOMEDICINE, 2016, 11 : 641 - 660
[28] Antitumor efficacy of arsenic/interferon in preclinical models of chronic myeloid leukemia resistant to tyrosine kinase inhibitors
El Eit, Rabab
Itani, Abdul Rahman
Nassar, Farah
Rasbieh, Nagham
Jabbour, Mark
Santina, Ahmad
Zaatari, Ghazi
Mahon, Francois-Xavier
Bazarbachi, Ali
Nasr, Rihab
CANCER, 2019, 125 (16) : 2818 - 2828
[29] Microenvironmental Factors Determine the Sensitivity of Acute Myeloid Leukemia Cells to Tyrosine Kinase Inhibitors
Shimada, Akira
Orwick, Shelley
Fujisaki, Hiroyuki
Campana, Dario
Baker, Sharyn D.
BLOOD, 2008, 112 (11) : 576 - 576
[30] FMS-Like Tyrosine Kinase 3 Inhibitors for the Treatment of Acute Myeloid Leukemia
Novatcheva, Elli D.
Anouty, Yasmine
Saunders, Ila
Mangan, James K.
Goodman, Aaron M.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 (03): : E161 - E184

← 1 2 3 4 5 →